The Treatment Action Group Pipeline Report provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV) and tuberculosis (TB).
Read the report on the Treatment Action Group website.
This joint letter calls on the Biden Administration to rapidly scale up mRNA vaccine manufacturing capacity to reach approximately 4 billion people by the end of 2021.
Quarraisha Abdool Karim, Ph.D. writes about the results of HPTN 083 and the implications of long-acting injectable of PrEP with cabotegravir in the New England Journal of Medicine.
The results of HPTN 083, a trial evaluating the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW), in the New England Journal of Medicine.
A quick but comprehensive slideshow review by AVAC Executive Director Mitchell Warren reviewing the state of HIV prevention, forthcoming products, and what needs to come next. Much accomplished; much to do.
Download the original PPT.
There are more biomedical strategies available for HIV prevention than ever before. At the same time, research is continuing. Trials must be able to test new tools and meet ethical standards by providing participants with the best available prevention package.
This episode of Px Pulse, Special Interview with AVAC’s Micheal Ighodaro, goes behind the scenes of the new HBO movie, The Legend of the Underground. The film documents the lives of AVACer Micheal Ighodaro and other LGBTQ Nigerians as they confront enormous risks to ‘live out loud’. As the movie unfolds, individual stories of resilience are woven together into a tapestry that portrays a revolution for cultural change in Nigeria.
No Data No More: Manifesto to Align HIV Prevention Research with Trans and Gender Diverse Realities, written and informed by trans and gender-diverse (TGD) activists from Cape Town to Berlin, with support and solidarity from AVAC, offers practical and essential priorities for demonstrable and viable HIV interventions for TGD people.
This manifesto reflects the urgent need for peer-led HIV prevention research with true ownership and acceptability in TGD communities.
Also available: download the Manifesto summary for a snapshot of key recommendations
The AMP trials evaluated the ability of a broadly neutralizing antibody (bNAb), called VRC01, to protect against HIV. The trials showed that VRC01 did not reduce the overall risk of acquiring HIV. However, VRC01 protected some individuals from infection by HIV viruses that were particularly vulnerable or “sensitive” to the antibody. Together these results mean AMP will inform future bNAb and vaccine studies. Read Understanding Results to learn more.
This episode of Px Pulse takes a deep dive into PEPFAR, The President’s Emergency Plan for AIDS Relief, looking at its pioneering successes and its challenges. In this episode, AVAC’s former Director of Strategy and Content, Emily Bass, discusses her new book, To End a Plague: America’s fight to end AIDS in Africa.